[CAS NO. 37762-06-4] Zaprinast
PRODUCTS SPECIFICATIONS [37762-06-4]
DESCRIPTION [37762-06-4]
Overview
| MDL | MFCD00214073 |
|---|---|
| Molecular Weight | 271.27 |
| Molecular Formula | C13H13N5O2 |
| SMILES | O=C1C(N=NN2)=C2N=C(C3=CC=CC=C3OCCC)N1 |
Summary
Zaprinast (M&B 22948) is an inhibitor of cGMP-selective Phosphodiesterases(PDEs) [1] . Zaprinast is a G protein-coupled receptor (GPR) 35 agonist which activates rat GPR35 strongly and activates human GPR35 moderately [2] . Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects [3] .
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
DMSO : 62.5 mg/mL ( 230.40 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.6864 mL | 18.4318 mL | 36.8636 mL |
| 5 mM | 0.7373 mL | 3.6864 mL | 7.3727 mL |
| 10 mM | 0.3686 mL | 1.8432 mL | 3.6864 mL |
References
- [1] Choi SH , et al. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res. 2002 Feb 1;67(3):411-21.
- [2] Taniguchi Y, et al. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 2006 Sep 18;580(21):5003-8. Epub 2006 Aug 17.
- [3] Keswani AN , et al The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects. J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):116-24.
Synonyms
